Ask AI
ProCE Banner Activity

Phase II/III RELATIVITY-047: Additional Response Results With Nivolumab ± Relatlimab in Previously Untreated Metastatic or Unresectable Melanoma

Conference Coverage
Slideset
Results from the phase II/III RELATIVITY-047 trial showed improvements in response rates and durable responses with the addition of relatlimab to nivolumab vs nivolumab alone in patients with previously untreated metastatic or unresectable melanoma.

Released: September 19, 2022

Share

Provided by

Provided by Clinical Care Options, LLC
ProCE Banner

Supporters

Supported by educational grants from

AstraZeneca

Bristol Myers Squibb

Exelixis, Inc.

Gilead Sciences, Inc.

Merck Sharp & Dohme Corp.